First oral, ghrelin-mimetic diagnostic test for adult growth hormone deficiency.
Also known as: Macrilen · AEZS-130 · ghrelin receptor agonist
Part of the Growth hormone & IGF peptides cluster
Overview
Macimorelin is an orally active ghrelin/growth hormone secretagogue receptor agonist. It was approved by the FDA in 2017 as a diagnostic agent that stimulates growth hormone release to help evaluate adult growth hormone deficiency. This page is educational and is not medical advice.
Source & context
Biological / chemical source: Synthetic orally active peptidomimetic
Primary research or clinical context: FDA-approved oral diagnostic agent for adult growth hormone deficiency (prescription)
A diagnostic, not a treatment
Macimorelin is used to provoke a measurable growth hormone response. Because it is taken by mouth, it offers a simpler alternative to older stimulation tests such as the insulin tolerance test for assessing adult GH deficiency.
Ghrelin-mimetic action
By activating the growth hormone secretagogue receptor, macimorelin mimics ghrelin's ability to trigger pituitary GH release. This links it conceptually to research GH secretagogues such as ipamorelin and the GHRP family.
FAQ about Macimorelin
What is Macimorelin?+
Macimorelin is an orally active ghrelin/growth hormone secretagogue receptor agonist. It was approved by the FDA in 2017 as a diagnostic agent that stimulates growth hormone release to help evaluate adult growth hormone deficiency. This page is educational and is not medical advice.
Is Macimorelin an approved medicine?+
Macimorelin: FDA-approved oral diagnostic agent for adult growth hormone deficiency (prescription). Always follow licensed medical guidance for approved products.
What is the typical length of Macimorelin?+
Macimorelin is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.